Although several potent and selective ATAD2 inhibitors have been reported, most lack appreciable cellular activity and druggability, especially in inhibiting tumour growth, which limits the clinical application of ATAD2 inhibitors. This evidence concerns the gene ATAD2 and neoplasm.